DPP-4 / SGLT2 / AMPK pathway (triple)

Class

Fixed-dose combination (DPP-4 inhibitor + SGLT2 inhibitor + biguanide)

This fixed-dose combination unites three complementary mechanisms used in type 2 diabetes, each acting on a different physiological defect that contributes to elevated blood glucose. A dipeptidyl peptidase-4 (DPP-4) inhibitor blocks an enzyme that normally degrades incretin hormones, prolonging their action to stimulate glucose-dependent insulin release and suppress glucagon. A sodium-glucose cotransporter-2 (SGLT2) inhibitor blocks glucose reabsorption in the kidney's proximal tubule, promoting its excretion in urine independent of insulin. The biguanide component activates AMP-activated protein kinase (AMPK), an intracellular energy sensor, which reduces glucose production by the liver and improves peripheral insulin sensitivity. Combining agents that act on incretin signaling, renal glucose handling, and hepatic/muscle energy metabolism addresses insulin secretion, insulin resistance, and glucose reabsorption simultaneously, rather than relying on a single pathway. This layered approach can produce additive glucose-lowering effects while potentially allowing each component to be used at a lower dose than if given alone, which may reduce class-specific side effects. Such multi-mechanism combinations are relevant wherever type 2 diabetes involves several coexisting physiological abnormalities, since single-pathway therapies often become insufficient as the disease progresses and glycemic control deteriorates over time.